Oct 9, 2026 08:30AM
Oct 9, 2026 08:30AM
Oct 6, 2026 09:20AM
Oct 1, 2026 09:02AM
Oct 1, 2026 09:01AM
Sep 11, 2026 07:00AM
Sep 10, 2026 09:10AM Outlook Therapeutics CEO discusses Lytenava FDA approval and U.S. launch
Sep 10, 2026 09:10AM
Aug 27, 2026 04:05PM
Aug 27, 2026 04:05PM
Aug 27, 2026 09:01AM
Aug 18, 2026 03:49PM
Aug 14, 2026 07:15AM
Aug 14, 2026 07:15AM Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA™
Aug 12, 2026 09:45PM
Aug 12, 2026 09:45PM
Aug 12, 2026 04:01PM
Aug 12, 2026 04:01PM
Aug 6, 2026 08:45AM
Jul 27, 2026 06:09AM
Jul 24, 2026 02:40PM FDA approves Outlook Therapeutics' Lytenava for wet AMD
Jul 24, 2026 02:40PM
Jun 16, 2026 08:02AM
Jun 16, 2026 08:02AM
Jun 1, 2026 08:47AM
Jun 1, 2026 08:46AM
May 28, 2026 04:00PM
May 28, 2026 04:00PM Outlook Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
May 26, 2026 07:03AM
May 26, 2026 07:00AM
May 18, 2026 06:08AM
May 15, 2026 04:05PM
Apr 23, 2026 04:05PM
Apr 23, 2026 04:05PM
Apr 22, 2026 08:30AM Outlook Therapeutics raises $5 million in registered direct offering
Apr 22, 2026 08:30AM
Apr 21, 2026 09:05AM
Apr 21, 2026 09:05AM
Apr 7, 2026 08:56AM
Apr 7, 2026 08:50AM
Apr 7, 2026 08:50AM
Mar 25, 2026 04:05PM Outlook Therapeutics closes $5 million public offering
Mar 25, 2026 04:05PM
Mar 24, 2026 07:00AM
Mar 24, 2026 07:00AM
Mar 23, 2026 05:30PM
Mar 23, 2026 05:30PM
Mar 16, 2026 08:06AM
Mar 16, 2026 08:05AM Outlook Therapeutics Announces New $18.4 Million Non-Convertible Note Financing and Amendment to Existing Convertible Note
Mar 5, 2026 04:16PM

334,274 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All